Insulin glargine

Lancet

Volumn 356, Issue 9228, 2000, Pages 443-445

  Bolli, Geremia B ^a   Owens, David R ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE; LONG ACTING DRUG; UNCLASSIFIED DRUG;

HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RETINOPATHY;

EID: 0034609223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02546-0     Document Type: Note

References (14)

1. GB Bolli RD Di Marchi GD Park S Pramming VA Koivisto Insulin analogues and their potential in the management of diabetes mellitus Diabetologia 42 1999 1151 1167
2. P Kurtzhals L Schäffer A Sörensen Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 2000 999 1005
3. LJ Slieker GS Brooke RD Di Marchi Modifications in the B10 and B26–30 regions of the B chain of human insulins alter affinity for the human IGF-1 receptor more than for the insulin receptor Diabetologia 40 suppl 2 1997 S54 S61
4. I Berti M Kellerer B Bossenmaier The long acting human insulin analog HOE 901: charactristics of insulin signalling in comparison to Asp(B10) and regular insulin Horm Metab Res 30 1998 123 129
5. LEH Smith W Shen C Peruzzi Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor Nat Med 5 1999 1390 1395
6. JC Pickup H Keen JA Parsons KGMM Alberti Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia BMJ 1 1978 204 207
7. M Lepore R Kurzhals S Pampanelli Pharmacokinetics and dynamics of s. c. injection of the long-acting insulin glargine (HOE901) in T1DM Diabetes 48 suppl 1 1999 A97
8. DR Owens A Barnett Designer insulins: Have they revolutionized insulin therapy? Betteridge JD Diabetes-current perspectives 1999 London Martin Dunitz
9. L Heinemann R Linkeschova K Rave B Hompesch M Sedlak T Heise Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 23 2000 6440 6449
10. T Pieber I Eugene-Jolchine E Derobert Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial Diabetes 47 suppl 1 1999 A62
11. RE Ratner IB Hirsch JL Neifing SK Garg TE Mecca CA Wilson Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes Diabetes Care 23 2000 639 643
12. H Yki-Järvinen A Dressier M Ziemen Study Group – HOE 901/3002. Comparison of insulin glargine (HOE901) vs NPH during 1 year of insulin combination therapy in Type 2 diabetes Diabetes 49 suppl 1 2000 A130
13. GB Bolli Rationale for using combinations of short-acting insulin analogue and NPH insulins at mealtime in the treatment of Type 1 diabetes mellitus J Ped Endocrinol Metab 12 suppl 3 1999 737 744
14. PM Jehle C Micheler DR Jehle D Breting BO Boehm Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens Lancet 354 1999 1604 1607